Laser by Aleya Launches New Laser-Based Acne Treatment Program for Hormonal Skin Conditions
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10732/258257_2b38cc3514c1e88b_001full.jpg
The new program uses non-ablative laser technology combined with personalized consultation and aftercare to support long-term skin recovery and confidence in clients experiencing hormonal skin disruptions.
"This launch was driven by client demand," said Aleya Bamdad, Founder and CEO of Laser by Aleya. "Many of our clients were struggling with recurring breakouts and inflammation tied to hormonal cycles, and we developed a targeted program to meet that need with the latest technology."
Service Overview
The program is now available and includes:
Skin consultation and sensitivity assessment
Non-ablative laser treatment for inflammation and discoloration
Support for acne-prone areas such as cheeks, jawline, and chin
Post-care regimen tailored to sensitive or healing skin
Treatments are performed by trained professionals using FDA-cleared laser systems suitable for a range of skin types.
Market Context
According to a 2023 publication in The Journal of Clinical and Aesthetic Dermatology, over 50% of women aged 20-40 report adult acne, much of it linked to hormonal shifts. Laser by Aleya developed this new offering in response to this segment's ongoing search for clinic-supported, longer-term skincare solutions.
About Laser by Aleya
Laser by Aleya is a leading provider of professional New York laser and electrolysis hair removal services in Great Neck. Committed to delivering safe, effective, and personalized treatments, Laser by Aleya uses advanced techniques to help clients achieve smooth, hair-free skin. Founded by Aleya Bamdad, a certified expert with 20 years of experience, Laser by Aleya focuses on client comfort, satisfaction, and results, setting the standard in quality hair removal services.
Contact Info
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Why Viking Therapeutics Stock Zoomed 5% Higher Today
Key Points Good news from a peer and a positive analyst update were the elements driving Viking Therapeutics (NASDAQ: VKTX) stock higher on the first trading day of the week. The clinical-stage biotech, closely watched by some because of its investigational weight-loss drug VK2735, saw its share price improve by more than 5% as a result. By contrast, the S&P 500 index basically traded flat across the trading session. What's good for the goose... The news driving Viking and other obesity drug developers came from a leading company in that space, Wegovy maker Novo Nordisk. Late Friday, the Denmark-based pharmaceutical announced that Wegovy earned approval from the U.S. Food and Drug Administration (FDA) to treat a new indication, noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a liver disorder. Companies like Viking and Novo Nordisk have been on the radar of many of an investor because of the obvious side benefits to obesity drugs. The latter company earning a fresh approval to treat a medical issue besides obesity provides a significant morale boost to shareholders of weight loss drug developers. Bullish stance reiterated Also improving sentiment on Viking stock was that new analyst note. Monday morning before market open, Piper Sandler 's Biren Amin reiterated his overweight (buy, in other words) recommendation and $71-per-share price target on the biotech. Amin's focus, according to reports, wasn't Novo Nordisk's recent news; rather, he was cheered by the prospects for VK2735. Viking is putting an oral version of the medication through clinical trials, and the readout of a phase 3 study is expected within this calendar quarter. In his estimation, if oral VK2735 continues to do well in testing and is brought to market, it could garner sales of $2.1 billion. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025
Globe and Mail
7 hours ago
- Globe and Mail
Buy, Hold, or Fade the Recent Rally in UnitedHealth Group (UNH) Stock?
UnitedHealth Group UNH stock is still down 40% year to date but has surged more than +20% this month following reports that Warren Buffett's Berkshire Hathaway BRK.B and other billionaire hedge fund managers have taken a stake in the company, including David Tepper's Appaloosa Management. In a classic value investing move, Buffett undoubtedly sees long-term value in UnitedHealth Group as a high-quality business at a steep discount, investing in other industry leaders during a crisis like Goldman Sachs GS during the 2008 financial meltdown and more recently Occidental Petroleum OXY during the Covid-19 pandemic plunge in energy prices. To that point, UnitedHealth has faced a DOJ investigation stemming from its health services and technology subsidiary Optum, and had previously suspended its full-year financial guidance due to unexpectedly high medical costs. Considering such, investors may be weighing the pros and cons of investing in UNH, with some wondering if it's time to fade the recent rally. UnitedHealth's Attractive Valuation & Balance Sheet As the parent company of United Healthcare, the nation's largest insurer, UnitedHealth Group stock had recently fallen toward its decade low in terms of price to forward earnings and is still on par with its 10-year foward P/E median of 18X. Furthermore, UNH trades at less than 1X sales and has the scale, diversification, and cash flow that are likely attracting Buffett and other large investors to believe in its long-term recovery. Notably, UnitedHealth Group has more than $32 billion in cash and equivalents on hand and over $308 billion in total assets compared to $208.1 billion in total liabilities. UNH EPS Revisions Despite reinstating its guidance, UnitedHealth Group now expects full-year fiscal 2025 EPS to be considerably lower at a least $16 per share, with the Zacks Consensus currently at $16.58 and falling 25% over the last 60 days from expectations of $22.28. While the drop in FY25 EPS estimates was expected, what may be more concerning to investors is that FY26 EPS estimates have dropped nearly 30% in the last two months from projections of $25.58 to $18.08. Conclusion & Final Thoughts The institutional pile into UnitedHealth Group stock may have set a psychological floor for investors, but the trend of declining EPS revisions does take away from the company's enticing valuation and suggests there could still be much better buying opportunities ahead. Correlating with such, it may be time to fade the recent rally, with UNH landing a Zacks Rank #5 (Strong Sell) at the moment. For investors who may be interested in limiting the short-term risk associated with the recent volatility in UnitedHealth Group stock, Zacks analyst Sanghamitra Saha has alluded to the notion that the iShares U.S. Healthcare Providers ETF IHF could be a better way to get exposure to UNH. Free Report: Profiting from the 2nd Wave of AI Explosion The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives. Investors who bought shares like Nvidia at the right time have had a shot at huge gains. But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies. Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI's next leap forward. Access AI Boom 2.0 now, absolutely free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report Occidental Petroleum Corporation (OXY): Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B): Free Stock Analysis Report iShares U.S. Healthcare Providers ETF (IHF): ETF Research Reports
CTV News
11 hours ago
- CTV News
U.S. patients can now get Ozempic for half price if they can pay cash
Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for US$499, for those who pay for medications on their own and don't go through insurance. The move comes as U.S. President Donald Trump is pressuring drugmakers to lower drug costs, which have long been a major health care headache for Americans. He and lawmakers have called out popular but pricey GLP-1 drugs, which are used for diabetes and weight loss, noting they are much more expensive in the United States than in other countries. Trump has also been pushing pharmaceutical manufacturers to provide medications directly to consumers at a lower price, cutting out insurers and other players. Novo Nordisk is making Ozempic, which carries a list price of just under $1,000 per month, available at its NovoCare Pharmacy, which ships medications directly to cash-paying consumers. The drugmaker earlier this year launched the direct-to-consumer pharmacy, offering Wegovy, its in-demand weight loss drug, for $499 a month. Rival Eli Lilly has also slashed the price of its GLP-1 weight loss drug, Zepbound, for self-pay patients. The discounted Ozempic price is also available on other platforms, including Novo Nordisk's website and through a partnership with GoodRx, which offers discounts on prescriptions at many pharmacies. The offer is open to eligible patients with an Ozempic prescription, the drugmaker said. Insurers are more likely to cover Ozempic for those with diabetes than they are Wegovy, and Novo Nordisk offers discounts for those with coverage. However, Novo Nordisk is looking to broaden Ozempic's availability even further. 'While Ozempic is well covered in the US, let's not forget that there are some patients who pay out-of-pocket for this vital medicine,' Dave Moore, executive vice president, of Novo Nordisk's U.S. operations, said in a statement. 'We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many.' The company noted in its second-quarter earnings call this month that compounding pharmacies, which are allowed to make versions of medications approved by the U.S. Food and Drug Administration when drugs are in shortage, have affected the sales of its GLP-1 medications. The FDA removed Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy, along with Eli Lilly's tirzepatide-based drugs, Zepbound and Mounjaro, from the shortage list. Novo Nordisk, however, said compounded versions continue to be sold. By Tami Luhby, CNN
